Literature DB >> 26600416

Toxic bile and sclerosing cholangitis: Is there a role for pharmacological interruption of the bile acid enterohepatic circulation?

Paul A Dawson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26600416      PMCID： PMC4718786          DOI： 10.1002/hep.28363

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  9 in total

1.  Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis.

Authors:  James H Tabibian; Steven P O'Hara; Christy E Trussoni; Pamela S Tietz; Patrick L Splinter; Taofic Mounajjed; Lee R Hagey; Nicholas F LaRusso
Journal:  Hepatology       Date:  2015-08-10       Impact factor: 17.425

2.  Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.

Authors:  Alexander G Miethke; Wujuan Zhang; Julia Simmons; Amy E Taylor; Tiffany Shi; Shiva Kumar Shanmukhappa; Rebekah Karns; Shana White; Anil G Jegga; Celine S Lages; Stephenson Nkinin; Bradley T Keller; Kenneth D R Setchell
Journal:  Hepatology       Date:  2015-08-21       Impact factor: 17.425

Review 3.  New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.

Authors:  Ulrich Beuers; Michael Trauner; Peter Jansen; Raoul Poupon
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 4.  The Cholangiopathies.

Authors:  Konstantinos N Lazaridis; Nicholas F LaRusso
Journal:  Mayo Clin Proc       Date:  2015-05-06       Impact factor: 7.616

Review 5.  Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs.

Authors:  Werner Kramer; Heiner Glombik
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 6.  Intestinal transport and metabolism of bile acids.

Authors:  Paul A Dawson; Saul J Karpen
Journal:  J Lipid Res       Date:  2014-09-10       Impact factor: 5.922

7.  Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.

Authors:  Anna Baghdasaryan; Claudia D Fuchs; Christoph H Österreicher; Ursula J Lemberger; Emina Halilbasic; Ingrid Påhlman; Hans Graffner; Elisabeth Krones; Peter Fickert; Annika Wahlström; Marcus Ståhlman; Gustav Paumgartner; Hanns-Ulrich Marschall; Michael Trauner
Journal:  J Hepatol       Date:  2015-10-31       Impact factor: 25.083

8.  A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.

Authors:  William D Chey; Michael Camilleri; Lin Chang; Leif Rikner; Hans Graffner
Journal:  Am J Gastroenterol       Date:  2011-05-24       Impact factor: 10.864

9.  Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.

Authors:  Mei Zhou; R Marc Learned; Stephen J Rossi; Alex M DePaoli; Hui Tian; Lei Ling
Journal:  Hepatology       Date:  2015-11-30       Impact factor: 17.425
  9 in total
  1 in total

Review 1.  Sex-related factors in autoimmune liver diseases.

Authors:  Dorothee Schwinge; Christoph Schramm
Journal:  Semin Immunopathol       Date:  2018-10-01       Impact factor: 9.623
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.